文献速递消化道肿瘤放疗

局部晚期直肠癌新辅助放化疗前后肿瘤测序:基因特征与临床结局

Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-11-22

本研究对17例局部晚期直肠癌患者新辅助放化疗前的活检组织及其中10例对应的术后切除标本进行708基因 panel 二代测序,比较驱动突变与肿瘤突变负荷的变化。结果显示95.2%的致癌驱动突变在治疗前后均检出,新辅助治疗后所有患者TMB下降,KRAS±TP53突变及TMB≥5与不良结局相关。

要点

  • 新辅助放化疗前后95.2%的致癌驱动突变持续存在,仅ATM和RYR1突变各一例治疗后未检出。
  • 新辅助治疗后所有患者肿瘤突变负荷下降,未观察到TMB升高。
  • KRAS±TP53突变及TMB≥5与不良结局相关。

核心结论

  • 大多数致癌驱动突变在新辅助治疗后持续存在,新辅助放化疗似乎不诱导大量新驱动突变或突变负荷增加,基因谱分析未来可能有助于肿瘤信息指导的方法和结局评估。

研究设计与样本

  • 对17例局部晚期直肠癌患者新辅助放化疗前的活检组织及其中10例对应的术后切除标本,使用包含708个基因的专用癌症 panel 进行二代测序,比较治疗前后致癌驱动突变和肿瘤突变负荷。

主要发现

  • 治疗前后配对的肿瘤样本中,95.2%的致癌驱动突变在两者中均可检出,一个ATM突变和一个RYR1突变在新辅助治疗后未检出。
  • 新辅助治疗后所有患者肿瘤突变负荷均下降。
  • KRAS±TP53突变和TMB≥5与不良结局相关。

临床怎么用

  • 原文结论指出基因谱分析未来可能有助于肿瘤信息指导的方法和结局评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Neoadjuvant chemoradiotherapy (NCRT) is a standard treatment option for locally advanced rectal cancer. However, there is still conflicting data about the genetic landscape and potential dynamics during and after NCRT. This study evaluated oncogenic driver mutations before NCRT and investigated corresponding resection samples after treatment. MATERIALS AND METHODS: In 17 patients the pre-therapeutic biopsy and in ten cases the related resection specimen were investigated by next-generation sequencing using a dedicated cancer panel (708 genes). Oncogenic driver mutations and tumor mutational burden (TMB) were compared pre- and post NCRT to evaluate stability of the genomic landscape. TMB and frequently detected driver mutations were correlated with outcome parameters. RESULTS: In our corresponding tumor samples before and after NCRT 95.2 % of the oncogenic driver mutations could be found in both specimens whereas one ATM and one RYR1 mutation were not detectable after NCRT. TMB decreased in all patients after neoadjuvant treatment. KRAS ± TP53 mutations and TMB ≥ 5 were associated with impaired outcome. CONCLUSION: Most oncogenic driver mutations investigated persisted after neoadjuvant treatment. At the same time, we did not observe ascending TMB after treatment but decline. Thus, NCRT does not seem to induce a relevant number of new driver mutations or mutational burden. Genetic profiling implies the potential to support tumor-informed approaches and outcome estimation in future.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Clasen K, Ballin N, Schütz L, et al. Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome. Clin Transl Radiat Oncol. 2024. PMID: 39670057. doi:10.1016/j.ctro.2024.100894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。